AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up. For 20 ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for immunology powerhouses Skyrizi and Rinvoq by $4 billion. The company now projects more than ...

Skyrizi is a key part of AbbVie's strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it has already lost protection from ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second ... thanks to just under $20 million spent on a trio of ads for the drug’s uses in treating depression and ...

With Skyrizi and Rinvoq achieving 51% and 50% growth respectively in 2024, and their combined sales expected to grow at more than a 20% compound annual rate through 2027, AbbVie's dividend looks ...